Global Information Inc. would like to present a new market research report, "Regenerative Medicine Markets" by Trimark Publications.
According to a new report from Trimark Publications, "Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made."In the field of
regenerative medicine (RM), laboratory-grown or therapeutically-induced human tissue replacements are used to treat diseased or injured human tissue. Previous efforts to mimic tissue repair and organ replacement solutions found in nature (i.e. starfish) have proven futile; however, "researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy." This study provides a comprehensive overview of the regenerative medicine sector and includes analyses of the funding trends, market opportunities, therapeutic pipeline, partnership activities, research collaborations, intellectual property, as well as guidelines for creating new ventures. Additionally, much of the discussion in this report surrounds tissue engineering and regenerative medicine (TERM), considering the former makes the latter possible. More specifically, TERM focuses on medical treatments to repair organs and tissues utilizing bioengineered materials, some implant forms, and cellular technologies.
Key questions addressed in this study:
- What is the current global market for regenerative medicine?
- How many companies are involved in the development of regenerative medicine products?
- What disease conditions offer the greatest potential for regenerative medicines?
- How long would it take to develop tissues on demand?
- What regulatory and technical challenges are being confronted by this industry?
- How many patents have been issued for regenerative medicine products?
- What is the most up-to-date position of the clinical studies and product pipe line in this sector?
- What are the requirements for the commercial manufacturing of regenerative medicine products?